In further support of a shift toward M1 activity, fulvestrant co-treatment with RT significantly elevated Nos2 transcripts, a marker for M1 macrophages, in the bulk tumor, compared to tumors treated with RT alone (Fig. 4I). This evidence concerns the gene NOS2 and neoplasm.